Literature DB >> 22285964

Phase II studies in soft tissue sarcoma: time for reappraisal.

Stefan Sleijfer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22285964      PMCID： PMC3286160          DOI： 10.1634/theoncologist.2011-0382

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  9 in total

1.  Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).

Authors:  Isabelle Ray-Coquard; Antoine Italiano; Emmanuelle Bompas; Axel Le Cesne; Yves-Marie Robin; Christine Chevreau; Jacques-Olivier Bay; Guilhem Bousquet; Sophie Piperno-Neumann; Nicolas Isambert; Laurent Lemaitre; Charles Fournier; Eric Gauthier; Olivier Collard; Didier Cupissol; Stéphanie Clisant; Jean-Yves Blay; Nicolas Penel
Journal:  Oncologist       Date:  2012-01-27

2.  Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).

Authors:  Corneel Coens; Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Ian Judson; Roberta Sanfilippo; Stephanie C Manson; Rachel A Hodge; Sandrine Marreaud; Judith B Prins; Iwona Lugowska; Saskia Litière; Andrew Bottomley
Journal:  Cancer       Date:  2015-05-29       Impact factor: 6.860

3.  Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.

Authors:  M Van Glabbeke; J Verweij; I Judson; O S Nielsen
Journal:  Eur J Cancer       Date:  2002-03       Impact factor: 9.162

Review 4.  Role of chemotherapy in the management of soft tissue sarcomas.

Authors:  Dimitrios Krikelis; Ian Judson
Journal:  Expert Rev Anticancer Ther       Date:  2010-02       Impact factor: 4.512

5.  Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.

Authors:  Axel Le Cesne; Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Michael Findlay; Peter Reichardt; Rolf Issels; Ian Judson; Patrick Schoffski; Serge Leyvraz; Binh Bui; Pancras C W Hogendoorn; Raf Sciot; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

6.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors:  Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Authors:  Stefan Sleijfer; Isabelle Ray-Coquard; Zsuzsa Papai; Axel Le Cesne; Michelle Scurr; Patrick Schöffski; Françoise Collin; Lini Pandite; Sandrine Marreaud; Annick De Brauwer; Martine van Glabbeke; Jaap Verweij; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.

Authors:  Cristina R Antonescu; Akihiko Yoshida; Tianhuo Guo; Ning-En Chang; Lei Zhang; Narasimhan P Agaram; Li-Xuan Qin; Murray F Brennan; Samuel Singer; Robert G Maki
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701
  9 in total
  4 in total

1.  Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan.

Authors:  Takamichi Ito; Hiroshi Uchi; Takeshi Nakahara; Gaku Tsuji; Yoshinao Oda; Akihito Hagihara; Masutaka Furue
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-25       Impact factor: 4.553

Review 2.  Management of Cutaneous Angiosarcoma: an Update Review.

Authors:  Siwei Bi; Ai Zhong; Xiya Yin; Jingyi Li; Ying Cen; Junjie Chen
Journal:  Curr Treat Options Oncol       Date:  2022-02-19

3.  Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma.

Authors:  Takamichi Ito; Kenichi Kohashi; Yuichi Yamada; Takeshi Iwasaki; Akira Maekawa; Masaaki Kuda; Daichi Hoshina; Riichiro Abe; Masutaka Furue; Yoshinao Oda
Journal:  J Cancer       Date:  2016-04-27       Impact factor: 4.207

4.  Primary Angiosarcoma of the Spleen: Rare Diagnosis with Atypical Clinical Course.

Authors:  Filip Kohutek; Ladislav Badik; Branislav Bystricky
Journal:  Case Rep Oncol Med       Date:  2016-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.